Approval of Beyonttra in Brazil brings new treatment options for ATTR-CM

The oral therapy acoramidis has been approved in Brazil, to be sold as Beyonttra, for treating adults with hereditary or wild-type transthyretin amyloid cardiomyopathy (ATTR-CM).

The regulatory clearance from the Agência Nacional de Vigilância Sanitária “marks an important step forward for Brazilian patients living with ATTR-CM,” Jonathan Fox, MD, PhD, president and chief medical officer of the cardiovascular and renal diseases program at Bridgebio, the therapy’s developer, said in a company press release announcing the agency’s decision.

“[This] is a particularly meaningful advance for patients living in Brazil who have long faced limited options for this progressive, life-threatening disease,” Fox said.